Genetic Variations of Tumor Necrosis Factor –α-308 and Lymphtoxin-α+252 in Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia Patients

Document Type: Original Article


1 School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

2 Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

3 Childeren Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

4 Tabriz branch, Islamic Azad University of Medical Science, Tabriz, Iran

5 Clinical Biochemistry Department, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

6 Tuberclosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

7 Hematology & Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran



Non- Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) are two main hematological malignances which have been driven from lymphoid tissue. Genetic polymorphisms in tumor necrosis factor-α (TNF-α) -308 and lymphotoxin-α (LT-α) +252 may affect their transcription and expression which leads to their high plasma level. The frequency of the TNF-α (-308) and LT-α (+ 252) polymorphisms are different for NHL and ALL cases in various populations with different ethnicity. This research is designed to investigate the prevalence and association of TNF-α (-308) and LT-α (+ 252) polymorphisms from NHL and ALL in Azarian patients and healthy individuals from Northwestern part of Iran.
Materials and Methods:
Seventy subjects with ALL and 68 NHL, along with another 130 healthy subjects as control group took part in this study. Genomic DNA was extracted, then genetic polymorphisms in TNF-α and LT-α genes were analyzed with the PCR-RFLP and NCOI as restriction enzyme. A statistical analysis was performed by chi-square test using SPSS software. A P-value of <0.05 was considered statistically significant.
Results: A statistically significant difference of LT-α polymorphism was in NHL patients and control (P-value= 0.008) but there was not any association of TNF-α polymorphism between NHL patients and control group. A significant association for TNF-a variant was in ALL and control (P-value =0.005), however, there was no relationship about LT variant between ALL and control.
The results show that there are significant differences between TNF-α (-308) and LT-α (+252) genetic polymorphisms respectively in ALL and NHL patients with control group from Northwestern part of Iran.


1. Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica 2007; 92: 960-969.

2. Ibrahim A, Abdel Rahman H, Khorshied M, Rania S, Nasr N, Khorshid O. Tumor necrosis factor alpha-308 and lymphotoxin alpha+252 genetic polymorphisms and the susceptibility to non-Hodgkin lymphoma in Egypt. Leuk Res 2012; 36:694-698.

3. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translation research. Hematology Am Soc Hematol Educ program 2009


4. CHAN JK .The new world health organization and classification of lymphoma: the past and present and the future. Hematol Oncol 2001; 19:129-150.

5. Morton LM, Purdue MP, Zheng T, Wang SS, Armstrong B, Zhang Y, Chatterjee N, et al . Risk of non-Hodgkin lymphoma associated with germ line

variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer of Epidemiol Biomarkers Prev 2009; 18:1259-1270.

6. Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G, et al. Prenatal origin of acute lymphoblastic leukemia in children. Lancet 1999; 354:1499-1503.

7. Sandler DP, Ross JA. Epidemiology of acute leukemia in children and adults. Semin Oncol 1997; 24:3-16.

8. Greaves M. Molecular genetics, natural history and the demise of childhood leukemia. Eur J Cancer 1999; 35:173-185.

9. Kadar K, Kovacs M, Karadi I, Melegh B, Pocsai Z, Mikala G , et al. Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res 2008; 32:1499-1504.

10. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, Whitby D, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Oxford J 2006; 28:704-712.

11. Hajeer AH, Hutchinson IV. TNF-α gene polymorphism: Clinical and biological implications. Microsc Res Tech 2000; 50:216-228.

12. Takeuchi S, Takeuchi N, Tsukasaki K, Bartram CR, Zimmermann M, Schrappe M, et al. Genetic polymorphisms in the tumour necrosis factor locus in childhood acute lymphoblastic leukaemia. Br J Hematol 2002; 119:985–957.

13. Kidas E, Moricke A, Beier R, Welte K, Schrappe M, Stanulla M, et al. Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study. Int J Hematol 2009; 89: 584-591.

14. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, et al. Genetic Polymorphisms in the Tumor Necrosis Factor Locus Influence Non-Hodgkin's Lymphoma Outcome. Blood 1998; 91:3574-3581.

15. Wang SS, Purdue MP, Cerhan JR, Zheng T, Menashe I, Armstrong B, et al. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor super families and NF-kB transcription factors and non-hodgkin lymphoma risk. PLoS One 2009; 4:e5360.

16. Cerhan JR, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007; 109:5439-5446.

17. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006; 7:27-38.

18. Jrad BB, Chatti A, Laatiri A, Ben Ahmed S, Romdhane A, Ajimi S, et al. Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin’s lymphomas. Eur J Hematol 2006; 78:117–122.

19. Wang SS, Slager SS, Brennan P, Holly EA, De Sanjose S, Bernstein L, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10211 cases

and 11905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 109:3479–3488.

20. Seidemann K, Zimmermann M, Book M, Meyer U, Burkhardt B, Welte K, et al. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-hodgkin's lymphoma: results from berlin-frankfurt-Munster Trial NHL-BFM 95. J Clin Oncol 2005; 23:8414-8421.

21. Zhao HY, Chen XY, Lin XB, Zhong XY, Zhong LY, Jiang WQ, et al. Relationship between tumor necrosis factor genetic polymorphisms and acute lymphocytic leukemia. Ai Zheng 2003; 22:861-866.

22. Stanulla M, Schrauder A, Welte K, Schrappe M. Tumor necrosis factor and lymphotoxin-alpha

genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy. BMC Blood Disorders 2001; 1


23. Skibola CF, Bracci PM, Nieters A, Brooks WA, Sanjos S, Hughes AM, et al. Tumor necrosis factor (TNF) and lymphotoxin-a (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the interLymph Consortium. Am J Epidemiol 2009; 171:267-276.

24. Cerhan JR, Wen LM, Zachary S, Novak AJ, Cunningham JM, Kay NE, et al. Genetic variation in tumor necrosis factor and the nuclear factor-kB canonical pathway and risk of non-Hodgkin's Lymphoma. Cancer Epidemiol Biomarkers Prev 2008; 17:3161-3169.